However, AR expression has also been detected in more aggressive and poorly differentiated tumors, particularly in cases that are estrogen receptor-negative, where ARs may contribute to tumor progression by modulating signaling pathways involved in cell-cycle regulation and survival [73,126]. Here, ESR1 is linked to neoplasm.